Another big step forward for the #MPSII community!
We’re delighted to share that the FDA has accepted the Biologics License Application for RGX-121, a potential first-in-class, one-time #GeneTherapy developed by our partners at @REGENXBIO!
Don't miss Dr. Aoki's presentation tomorrow at 5:30pm in Poster Hall I2. They'll be sharing results from the NS-089 clinical trial, offering new insights into potential therapies for #Duchenne muscular dystrophy.
A warm #Welcome to Heather Greenberg, our new Associate Director of the Patient Services Hub!
Heather brings 20+ years of expertise in patient access and reimbursement, notably in #RareDiseases! Outside of work, she's a passionate runner and beach lover.
Meet Ross, our new Director of Market Access Marketing!
Ross brings 20+ years of pharma commercial leadership experience across sales, operations, marketing, and market access. When he’s not at work, he enjoys spending time with his family.
We are proud to be joining @REGENXBIO as a Visionary sponsor of the 2025 @Projectalive Building A Future Together MPS II Community Conference this weekend, bringing together members of the Hunter syndrome community for a day of learning, connection and fun. Hope to see you there! https://x.com/NSPharmaInc/status/1918322518185873656/photo/1